The abstract is read at the publisher; the summary is JClub's.
Rapamycin at 20 M mitigates amyloid-beta proteotoxicity in Caenorhabditis elegans, delaying paralysis and improving locomotion in CL4176 and CL2355 models.
- Why it matters: No therapy halts AD neurodegeneration, and it is unclear whether rapamycin’s protection depends on lowering amyloid-beta burden or other, amyloid-independent mechanisms.
- What they did: In two transgenic C. elegans Aβ expression strains (CL4176 temperature-inducible muscle-specific; CL2355 pan-neuronal), rapamycin was tested for effects on paralysis, locomotion, chemotaxis, survival, and health span, with Aβ burden measured molecularly.
- The result: Rapamycin delayed Aβ-induced paralysis (log-rank p = 0.0001), improved locomotion, rescued CL2355 chemotaxis deficit (one-way ANOVA p = 0.008), extended Kaplan–Meier survival and locomotor health span, while not significantly changing Aβ burden.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.